Gene therapy is a big and trending topic in the world of medicine and has recently been making headlines as large pharmaceutical companies have been ramping up acquisitions of gene therapy companies. So how exactly does gene therapy work? There are a couple of “traditional” approaches to this generally newer treatment option for rare diseases and cancer….
TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade
AUSTIN, Texas & CAMBRIDGE, Mass.— (April 8, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, reported that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019….
AUSTIN, Texas & CAMBRIDGE, Mass.— (April 1, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission….